Medicare Part D Redesign Backed By House Republicans Retools Manufacturer Discount
Executive Summary
Failed amendment offered by House Energy & Commerce Committee’s ranking Republican during markup of Speaker Nancy Pelosi’s drug pricing bill, the proposal is in line with biopharma’s position on manufacturer price concessions in Part D and suggests a road map for the kind of bill that might pass the Senate.
You may also be interested in...
US Biosimilars Market Is On A Solid Footing, 10 Years In
The market for biosimilars in the US appears to be improving, industry leaders said during a panel on biosimilars at the BIO 2020 digital meeting.
US Biosimilars Market Is On Solid Footing, 10 Years In
The market for biosimilars in the US appears to be improving, industry leaders said during a panel on biosimilars at the BIO 2020 digital meeting.
Sandoz Looks To Biosimilars As It Reprioritizes In The US
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.